Molecular Classification Based on the Gene Expression Profiles in Canine Histiocytic Sarcoma Cells.

Area of Science:

• Veterinary Oncology
• Molecular Biology
• Canine Cancer Research

Background:

• Canine histiocytic sarcoma (CHS) molecular underpinnings are not fully understood.
• Previous studies showed variable drug sensitivities among CHS cell lines, hinting at diverse molecular abnormalities.
• Investigating these differences is crucial for developing effective treatments.

Purpose of the Study:

• To classify canine histiocytic sarcoma (CHS) cell lines based on gene expression profiles (GEPs).
• To identify molecular differences associated with distinct CHS subtypes.
• To explore potential therapeutic strategies based on identified molecular pathways.

Main Methods:

• RNA sequencing analysis of 11 CHS cell lines to generate GEPs.
• Clustering analysis to group cell lines based on GEPs.
• Differential gene expression analysis and RT-qPCR validation for key genes.
• Examination of NF-κB pathway activation status (p65 nuclear translocation, CCL5 release).

Main Results:

• CHS cell lines clustered into two distinct groups based on GEPs.
• 675 differentially expressed genes (DEGs) were identified, enriched in inflammatory response pathways.
• NF-κB pathway activation, indicated by p65 nuclear translocation and CCL5 release, distinguished one cluster.
• No significant difference in Akt or ERK pathway activation was observed between clusters.

Conclusions:

• Canine histiocytic sarcoma (CHS) exhibits molecular heterogeneity, potentially classifiable into two subtypes based on NF-κB pathway activation.
• These findings support the development of precision medicine tailored to specific molecular subtypes of CHS.
• Further research into these subtypes could lead to more targeted and effective therapeutic interventions.